Clinical Trial

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Study acronym: ReLaPSe
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-22; most recent amendment 2026-07-14.
Trial Details
NCT Number NCT07377747
Lead Sponsor Australia and New Zealand Sarcoma Association
Conditions Retroperitoneal Liposarcoma
Enrollment 100 participants
Start Date 2024-09-05
Primary Completion 2032-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-15